Aurobindo Pharma Faces USFDA Scrutiny: 11 Observations Issued for Raleigh Plant

Aurobindo Pharma has disclosed that the United States Food and Drug Administration (USFDA) conducted an inspection at its Raleigh-based manufacturing facility, operated by its subsidiary Aurolife Pharma LLC. Following the inspection, the USFDA issued a Form 483 with 11 observations, highlighting areas of concern that require corrective action.

The Raleigh plant specializes in producing metered dose inhalers and dermatological products, making it a critical component of Aurobindo Pharma's global operations. The observations pertain to procedural and compliance issues, which the company is now addressing to align with regulatory standards. Aurobindo Pharma has assured stakeholders of its commitment to resolving these observations promptly and maintaining high-quality manufacturing practices.

Key highlights include:
- The issuance of 11 observations by the USFDA, emphasizing the need for procedural improvements.
- The Raleigh facility's role in producing specialized pharmaceutical products for the US market.
- Aurobindo Pharma's proactive approach to addressing regulatory concerns and ensuring compliance.

This development underscores the importance of stringent quality control and adherence to regulatory guidelines in the pharmaceutical industry.

Sources: India Infoline, The Health Master, Business Standard.